Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Current Liabilities (2021 - 2025)

Krystal Biotech's Total Current Liabilities history spans 5 years, with the latest figure at $102.9 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 0.93% year-over-year to $102.9 million; the TTM value through Dec 2025 reached $102.9 million, up 0.93%, while the annual FY2025 figure was $102.9 million, 0.93% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $102.9 million at Krystal Biotech, up from $102.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $102.9 million in Q4 2025 and bottomed at $9.1 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $31.0 million (2022), against an average of $49.1 million.
  • The largest annual shift saw Total Current Liabilities surged 208.2% in 2024 before it increased 0.93% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $25.7 million in 2021, then grew by 12.09% to $28.8 million in 2022, then rose by 14.72% to $33.1 million in 2023, then soared by 208.2% to $102.0 million in 2024, then grew by 0.93% to $102.9 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Total Current Liabilities are $102.9 million (Q4 2025), $102.0 million (Q4 2024), and $89.5 million (Q3 2024).